How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 29 Mar | 06 Apr | 04 May | 26 Jun | 06 Jul | 11 Jul | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 85.7 | 85.7 | 84.5 | 80.2 | 80.2 | 76.9 | -8.7 |
| Healthcare | 11.2 | 11.2 | 12.1 | 18.4 | 18.4 | 17.8 | +6.6 |
| Chemicals | 1.2 | 1.2 | 1.1 | 1.2 | 1.2 | 1.3 | +0.2 |
| Unclassified | 0.0 | 0.0 | 0.0 | · | · | · | +0.0 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 12.20% | 10 | 8 | 6 | 4 | 2 | 1/2 | +13.9% |
| DRREDDY | Pharma | 8.22% | 7 | 2 | 5 | 1 | 7 | 0/2 | -0.3% |
| MANKIND | Pharma | 6.98% | 10 | 8 | 9 | 5 | 2 | 0/2 | +18.5% |
| CIPLA | Pharma | 6.67% | 6 | 3 | 5 | 3 | 6 | 0/2 | +13.9% |
| ALKEM | Pharma | 5.67% | 9 | 8 | 8 | 10 | 6 | 1/2 | +0.5% |
| DIVISLAB | Pharma | 5.57% | 10 | 8 | 1 | 6 | 1 | 1/2 | +8.1% |
| COHANCE | Healthcare | 4.31% | 4 | 5 | 4 | 10 | 4 | 0/2 | +13.2% |
| MAXHEALTH | Healthcare | 3.10% | 7 | 9 | 5 | 4 | 3 | 0/2 | +12.2% |
| SYNGENE | Healthcare | 2.89% | 2 | 3 | 6 | 9 | 7 | 0/2 | -0.6% |
| BIOCON | Pharma | 2.59% | 6 | 1 | 10 | 5 | 3 | 0/2 | +12.5% |
| ABBOTINDIA | Pharma | 2.47% | 4 | 9 | — | 8 | 7 | 0/2 | +0.6% |
| LUPIN | Pharma | 2.30% | 10 | 10 | 10 | 6 | 7 | 1/2 | +4.0% |
| PFIZER | Healthcare | 1.86% | 3 | 7 | 1 | 2 | 7 | 0/2 | -9.0% |
| JBCHEPHARM | Pharma | 1.56% | 9 | 7 | 2 | 5 | 1 | 1/2 | +18.6% |
| BLUEJET | Pharma | 1.51% | 6 | 10 | 1 | 2 | 5 | 0/2 | +37.9% |
| RAINBOW | Healthcare | 1.44% | 10 | 7 | 2 | 5 | 4 | 1/2 | +15.3% |
| AUROPHARMA | Pharma | 1.17% | 9 | 3 | 10 | 6 | 6 | 0/2 | +14.4% |
Performance · 5.0y
Over the last 5.0 years ₹100 in the fund grew to ₹209 (+109%), vs ₹169 for Nifty 500 (+69%) and ₹152 for Nifty 50 (+52%). Its relative-strength line ended at 137 vs Nifty 50 and 123 vs Nifty 500 — above 100, sustained outperformance.